Clofarabine has apoptotic effect on T47D breast cancer cell line via P53R2 gene expression

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 4, 2015, Pages 471-476

  Rahmati Yamchi, Mohammad ^a,b   Zarghami, Nosratollah ^b   Charoudeh, Hojjatollah Nozad ^c   Ahmadi, Yasin ^a,b   Baradaran, Behzad ^a   Khalaj Kondori, Mohammad ^d   Milani, Morteza ^e   Akbarzadeh, Abolfazl ^e   Shaker, Maghsud ^b   Pourhassan Moghaddam, Mohammad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TABRIZ   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Breast Cancer; DNA damage; P53R2

Indexed keywords

CLOFARABINE; LIPOCORTIN 5; PROPIDIUM IODIDE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; INCUBATION TIME; MTT ASSAY; P53R2 GENE; REAL TIME POLYMERASE CHAIN REACTION; T47D CELL LINE;

EID: 84949676122     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.064     Document Type: Article

References (25)

1. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24(12):1917-23. doi: 10.1200/JCO.2005.03.8554
2. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78(11):1351-9. doi: 10.1016/j.bcp.2009.06.094
3. Nagai S, Takenaka K, Nachagari D, Rose C, Domoney K, Sun D, et al. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011;71(5):1781-91. doi: 10.1158/0008-5472.CAN-10-1919
4. Pui CH, Jeha S. Clofarabine. Nat Rev Drug Discov 2005;Suppl:S12-3.
5. Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer 2005;103(10):1985-95. doi: 10.1002/cncr.21005
6. Wang X, Zhenchuk A, Wiman KG. Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett 2009;276(1):1-7. doi: 10.1016/j.canlet.2008.07.019
7. Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett 2003;190(2):233-43. doi: 10.1016/s0304-3835(02)00588-8
8. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004;95(1):7-11. doi: 10.1111/j.1349-7006.2004.tb03163.x
9. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63(20):6583-94.
10. Hakansson P, Hofer A, Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 2006;281(12):7834-41. doi: 10.1074/jbc.M512894200
11. Nakano K, Bálint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000;19(37):4283-9. doi: 10.1038/sj.onc.1203774
12. Xue L, Zhou B, Liu X, Heung Y, Chau J, Chu E, et al. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res 2007;67(1):16-21. doi: 10.1158/0008-5472.CAN-06-3200
13. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61(22):8256-62.
14. Chang L, Zhou B, Hu S, Guo R, Liu X, Jones SN, et al. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc Natl Acad Sci U S A 2008;105(47):18519-24. doi: 10.1073/pnas.0803313105
15. Zhang K, Wu J, Wu X, Wang X, Wang Y, Zhou N, et al. P53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol Cancer Ther 2011;10(2):269-78. doi: 10.1158/1535-7163.MCT-10-0728
16. Pontarin G, Ferraro P, Bee L, Reichard P, Bianchi V. Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. Proc Natl Acad Sci U S A 2012;109(33):13302-7. doi: 10.1073/pnas.1211289109
17. Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 2010;57(6):885-92. doi: 10.1111/j.1365-2559.2010.03725.x
18. Wang X, Liu X, Xue L, Zhang K, Kuo ML, Hu S, et al. Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells. Biochem Biophys Res Commun 2011;410(1):102-7. doi: 10.1016/j.bbrc.2011.05.114
19. Thelander L. Ribonucleotide reductase and mitochondrial DNA synthesis. Nat Genet 2007;39(6):703-4. doi: 10.1038/ng0607-703
20. Piao C, Jin M, Kim HB, Lee SM, Amatya PN, Hyun JW, et al. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene 2009;28(21):2173-84. doi: 10.1038/onc.2009.84
21. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773(8):1263-84. doi: 10.1016/j.bbamcr.2006.10.001
22. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: New concepts of activation. Biol Cell 2001;93(1-2):53-62. doi: 10.1016/s0248-4900(01)01125-x
23. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA 3rd, Weitman S. Discovery and development of clofarabine: A nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5(10):855-63. doi: 10.1038/nrd2055
24. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21(6):1167-73. doi: 10.1200/jco.2003.04.031
25. Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B, Cebula-Obrzut B, Smolewski P, Fabianowska-Majewska K. Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells. Eur J Pharmacol 2014;723:276-87. doi: 10.1016/j.ejphar.2013.11.021